OS Therapies refiles IPO for a modest $6M to fund phase 2 HER2 drug, preclinical ADCs 01.08.2024 12:20 Fiercebiotech.com OS Therapies refiles IPO for a modest $6M to fund phase 2 HER2 drug, preclinical ADCs jwaldron Thu, 08/01/2024 - 05:20
